← Browse by Condition
Medical Condition

metastatic castration sensitive prostate cancer mcspc

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3
NCT07028853 Phase 3
Recruiting

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Enrollment
1,000 pts
Location
United States, Argen...
Sponsor
Pfizer
View Trial →